Product
Efzofitimod
Aliases
ATYR1923, Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, KRP-R120
4 clinical trials
3 indications
Indication
SarcoidosisIndication
Interstitial Lung DiseaseIndication
COVID-19Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisStatus: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
Randomized, Double-blind, Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)Status: Completed, Estimated PCD: 2020-10-23
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary SarcoidosisStatus: Completed, Estimated PCD: 2021-06-29